CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 5 enrolled
Drug / intervention
Gemcitabine +1 moredrug
Likely dose
Gemcitabine 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00630409
NCT00630409Phase 2Completed
CompareCT.gov

Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma

University of Pittsburgh·interventional·Posted Mar 7, 2008·Updated Mar 10, 2017

In Brief

A Phase 2 clinical trial evaluating Gemcitabine and Doxil for Metastatic Renal Cell Carcinoma. Completed, enrolled 5 participants across 1 site.

Detailed Summary

The purpose of this study is to test the hypothesis that the combination of gemcitabine and doxil will have clinical activity in patients with metastatic renal cell carcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Renal Cell Carcinoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 7, 2008
Enrollment StartSep 1, 2004
Primary CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 18.3 years ago

Interventions

Gemcitabinedrug

800 mg IV day 1 and 8

Doxildrug

24 mg/m2 every 21 days IV